Hangzhou Jingjiahang Biomedical Technology Co., Ltd. has successfully completed an angel round funding of tens of millions of yuan, led by Hangzhou Capital Asset Management, with participation from Zhengjing Capital and Binjiang 5050. The proceeds from this funding will primarily be allocated towards the preclinical and early clinical development of the company's existing product pipelines.